申请人:Hashimoto Hiromasa
公开号:US20070032497A1
公开(公告)日:2007-02-08
The present invention provides a fused ring compound of the following formula [I]
wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.
本发明提供了以下式[I]的融合环化合物,其中每个符号如规范中定义的,其药学上可接受的盐以及包含该化合物的丙型肝炎治疗剂。本发明的化合物显示出基于丙型肝炎病毒(HCV)聚合酶抑制活性的抗HCV作用,并且可用作丙型肝炎的治疗剂或预防剂。